SHERP

Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix

Cited 0 time in webofscience Cited 34 time in scopus
Authors
Lee, Me-Yeon; Wu, Hong-Gyun; Kim, Kyubo; Ha, Sung Whan; Kim, Jae Sung; Kim, In Ah; Lee, Hyo-Pyo
Issue Date
2006-09-26
Publisher
Academic Press;
Elsevier
Citation
Gynecol Oncol 2007;104:95-9
Keywords
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy Protocols/adverseeffects/*therapeutic useCarboplatin/administration & dosage/adverse effectsCarcinoma, Squamous Cell/*drug therapy/pathology/*radiotherapyCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm StagingPaclitaxel/administration & dosage/adverse effectsRetrospective StudiesSurvival RateUterine Cervical Neoplasms/*drug therapy/pathology/*radiotherapy
Abstract
OBJECTIVES: To evaluate the toxicity and the efficacy of paclitaxel/carboplatin chemoradiotherapy as a definitive treatment for squamous cell cancer of the uterine cervix. METHODS: From March 2000 to January 2004, 33 patients with squamous cell cancer of the uterine cervix were treated with concurrent chemoradiotherapy including 2 cycles of paclitaxel (135 mg/m(2)) and carboplatin (area under the time-concentration curve 4.5 mg min/ml) at 4-week interval. Seven patients received adjuvant chemotherapy with the same chemotherapeutic regimen. All patients received external beam radiotherapy with 41.4-51.4 Gy (median 50.4 Gy) to the whole pelvis. Twenty-eight patients received boost irradiation to the cervix by brachytherapy with 25.6-43.3 Gy (median 34.6 Gy) and 5 patients by external beam radiotherapy with 10.8-14.4 Gy (median 14.4 Gy). RESULTS: A median follow-up period was 27 months (range: 6-53 months). Acute hematological toxicity of grade 3 or 4 developed in 20 patients (61%), and acute gastrointestinal toxicity of grade 3 developed in 1 patient (3%). Vesicovaginal fistula occurred in 2 patients (6%). All patients achieved objective response (CR 70%, PR 30%) in 2 months after termination of treatment. One patient had a local progression in cervix, and 4 patients developed distant metastases. The 3-year estimated disease-free survival rates for stages I-IIA, IIB, III and IV were 67%, 91%, 88% and 50%, respectively. The 3-year estimated survival rates for stages I-IIA, IIB, III and IV were 89%, 91%, 88% and 50%, respectively. CONCLUSION: Concurrent chemoradiotherapy with paclitaxel and carboplatin is effective to achieve an excellent pelvic control.
ISSN
0090-8258 (Print)
Language
English
URI
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WG6-4KY88DW-5&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=77ea887a3c803f82d0a977ef668ea8f7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16996117

http://hdl.handle.net/10371/10445
DOI
https://doi.org/10.1016/j.ygyno.2006.07.021
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Radiation Applied Life Science (대학원 협동과정 방사선응용생명과학전공)Journal Papers (저널논문_방사선응용생명과학)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse